{"filing":{"accession_number":"0001490978-26-000067","cik":"0001490978","ticker":"SDGR","company_name":"Schrodinger, Inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"sdgr-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1490978/000149097826000067/sdgr-20260805.htm"},"events":[{"id":24871,"run_id":22546,"accession_number":"0001490978-26-000067","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Schrödinger's second quarter 2026 financial results, including ACV of $29.6 million (27% growth), software revenue of $32.5 million, drug discovery revenue of $23.0 million, total revenue of $58.9 million (8% increase), and net income of $6.0 million. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing includes detailed financial highlights, operational metrics, forward guidance for 2026 and Q3, and recent business developments.","company_name":"Schrodinger, Inc.","ticker":"SDGR","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25563,"accession_number":"0001490978-26-000067","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Schrödinger's second quarter 2026 financial results, including ACV of $29.6 million (27% growth), software revenue of $32.5 million, drug discovery revenue of $23.0 million, total revenue of $58.9 million (8% increase), and net income of $6.0 million. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing includes detailed financial highlights, operational metrics, forward guidance for 2026 and Q3, and recent business developments.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:31:50.585174+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25563,"accession_number":"0001490978-26-000067","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Schrödinger's second quarter 2026 financial results, including ACV of $29.6 million (27% growth), software revenue of $32.5 million, drug discovery revenue of $23.0 million, total revenue of $58.9 million (8% increase), and net income of $6.0 million. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing includes detailed financial highlights, operational metrics, forward guidance for 2026 and Q3, and recent business developments.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:31:50.585174+00:00","company_name":"Schrodinger, Inc.","ticker":"SDGR","filing_date":"2026-08-05"}]}